SPRINGWORKS THERAPEUTICS, INC. Selling, General and Administrative Expense
SPRINGWORKS THERAPEUTICS, INC. reported Selling, General and Administrative Expense of $76.50 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-05-09
- SPRINGWORKS THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-03-31 was $76.50M, a 27.26% increase year-over-year.
- SPRINGWORKS THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2024-12-31 was $77.10M, a 28.85% increase year-over-year.
- SPRINGWORKS THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2024-09-30 was $61.60M, a 32.34% increase year-over-year.
- SPRINGWORKS THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2024-06-30 was $57.84M, a 23.08% increase year-over-year.
- SPRINGWORKS THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $256.65M, a 29.92% increase from fiscal 2023.
- SPRINGWORKS THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $197.55M, a 46.82% increase from fiscal 2022.
- SPRINGWORKS THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $134.55M, a 87.42% increase from fiscal 2021.
- SPRINGWORKS THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2021 was $71.79M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2025-03-31 | $76.50M 10-Q · filed 2025-05-09 | $153.60M derived: sum of 2 quarters · filed 2025-05-09 | $215.20M derived: sum of 3 quarters · filed 2025-05-09 | $273.04M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | $77.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $138.70M derived: sum of 2 quarters · filed 2025-02-20 | $196.54M derived: sum of 3 quarters · filed 2025-02-20 | $256.65M 10-K · filed 2025-02-20 |
| 2024-09-30 | $61.60M 10-Q · filed 2024-11-12 | $119.44M derived: sum of 2 quarters · filed 2024-11-12 | $179.55M 10-Q · filed 2024-11-12 | $239.39M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-06-30 | $57.84M 10-Q · filed 2024-08-07 | $117.95M 10-Q · filed 2024-08-07 | $177.79M derived: sum of 3 quarters · filed 2025-05-09 | $224.33M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-03-31 | $60.11M 10-Q · filed 2025-05-09 | $119.95M derived: sum of 2 quarters · filed 2025-05-09 | $166.50M derived: sum of 3 quarters · filed 2025-05-09 | $213.49M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $59.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $106.38M derived: sum of 2 quarters · filed 2025-02-20 | $153.38M derived: sum of 3 quarters · filed 2025-02-20 | $197.55M 10-K · filed 2025-02-20 |
| 2023-09-30 | $46.55M 10-Q · filed 2024-11-12 | $93.54M derived: sum of 2 quarters · filed 2024-11-12 | $137.72M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $46.99M 10-Q · filed 2024-08-07 | $91.17M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $44.17M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $134.55M 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $71.79M 10-K · filed 2024-02-27 |